tirzepatide surpass SURPASS-CVOT trial: For patients with high-risk type 2 diabetes, the effect of tirzepatide, a dual agonist of the GLP-1 and glucose-dependent insulinotropic polypeptide receptors, on cardiovascular outcomes is uncertain. Research is summarized Reduction of prevalence of patients
Description
A manufacturer expiration date applies to FDA-approved products like Mounjaro and Zepbound
If you take a break from your medication and then start taking it again, you may experience the same side effects that you experienced when you first started taking it
According to the product information, gastrointestinal symptoms are common, with nausea affecting a significant proportion of patients, though symptoms often diminish over time as the body adjusts
When appetite and food behaviour shift, associated habits sometimes shift with them
